NPRA’s Facilitated Registration Pathway: FDA and EMA Drugs in 90 Days

C Y, Business Development Director | Infinity Pharmacare

Foreign manufacturers with a US FDA or EMA approval can now register in Malaysia far faster than the headline timeline suggests. The Facilitated Registration Pathway Abbreviated Review targets 90 working days, against 245 for a standard full evaluation, and a pilot launched on 2 May 2026 targets 60. The strategic decision is no longer whether Malaysia will recognise your dossier. It is which reliance route applies, and who holds the registration once it is granted.

Malaysia’s registration architecture has matured quietly. The Facilitated Registration Pathway (FRP), first published in March 2019 and revised in November 2023, now sits formally inside the Drug Registration Guidance Document (DRGD), 3rd Edition, 11th Revision, dated January 2026. The new Recognition Procedure Pilot adds a faster but stricter option on top. Understanding where each route fits, and where the constraints bite, is the prerequisite for any credible 2026 entry plan.

What does Malaysia’s facilitated registration architecture actually consist of?

The National Pharmaceutical Regulatory Agency (NPRA) is Malaysia’s drug regulatory authority under the Ministry of Health. It currently offers three routes under or adjacent to the FRP framework, each with a different eligibility threshold and timeline. The FRP itself is NPRA’s reliance based review framework, where NPRA leans on the prior assessment of a trusted foreign regulator rather than repeating the full evaluation.

The standard Full Evaluation is the baseline at 245 working days for new chemical entities and biologics, per DRGD Section 10.3. It carries no prior-approval shortcut.

The FRP Abbreviated Review relies on prior assessment by one of seven named reference agencies: the EMA, the US FDA, the UK MHRA, the TGA in Australia, the PMDA in Japan, Health Canada, and Swissmedic. It does not include HSA Singapore. The target is 90 working days. These routes are formally incorporated into the DRGD via Appendix 14, which details “Full Evaluation via Facilitated Registration Pathway (Abbreviated and Verification Review).” For most established EU and US manufacturers, this is the route to evaluate first.

Parameter	Full Evaluation	FRP Abbreviated Review	Recognition Pilot (2026)
Basis	DRGD 3rd Ed., 11th Rev., Section 10.3	FRP Guideline Nov 2023; DRGD Appendix 14	NPRA pilot announcement, May 2026
Eligibility	New chemical entities and biologics	Products assessed by a listed reference agency	Products approved by US FDA and EMA only
Reference agencies	None required	EMA, US FDA, UK MHRA, TGA, PMDA, Health Canada, Swissmedic (seven)	US FDA and EMA only
Timeline	245 working days	90 working days	Target 60 working days
Submission window	Standard	Standard	Within 3 months of reference agency approval
Status	Codified	Codified	One-year pilot, not yet codified

Why does the reference agency list matter more than the timeline?

The 60 working day pilot headline is commercially attractive. The constraint that decides eligibility is the reference agency list, not the timeline.

A product approved by Health Canada qualifies for the FRP Abbreviated Review at a 90 working day target, but not for the Recognition Pilot. A product approved by the EMA qualifies for both. The UK MHRA sits on the Abbreviated Review list but is not named in the pilot, which is FDA and EMA only. So a manufacturer holding UK approval but not yet EMA approval should plan around the Abbreviated Review, not the pilot.

There is a prior gate that catches manufacturers who plan the Malaysian filing in isolation. For Full Evaluation under Conditional Registration of new drugs and biologics, the product must already be registered in at least one Drug Control Authority reference agency at the point of submission, per Appendix 14, Section 2(b). The Drug Control Authority (DCA) is Malaysia’s statutory body that grants product registration. In short, your foreign approval is the entry ticket for these routes, not a bonus. Sequence your global filings so a qualifying reference approval is in hand before you submit in Malaysia.

What does this mean for your 2026 filing and your PRH decision?

Pick the route from your approval history and your timeline pressure. If your FDA or EMA approval is less than three months old and speed is commercially material, stress-test the 60 working day pilot now, since the window is time-limited and NPRA has not committed to making it permanent. If your approval is older, or sits with one of the other five reference agencies, the codified 90 working day Abbreviated Review is the dependable route.

Reliance logic also runs into the post-registration life cycle, where manufacturers often lose time. For additional indications, DRGD Section 20.4 provides four evaluation routes: Standard Full Evaluation, Reliance Full Evaluation, Standard Verification, and Reliance Verification. For variations, Section 20.1.3 sets three tiers as maximum limits: not more than 80 working days without major variation categories, not more than 100 with them, and not more than 150 for applications with more than ten major variation categories. Knowing your tier lets you plan label and supply changes against a realistic ceiling.

The variable that decides whether any of this speed converts into control sits outside the guideline documents. A Product Registration Holder (PRH) is the legal entity that holds the registration and bears regulatory accountability for a registered product in Malaysia. A faster review only accelerates the moment at which someone holds your registration. If that someone is a distributor rather than a structure you control, you have bought speed at the cost of ownership, and unwinding a PRH arrangement later tends to be slow and costly. The same principle applies to medical devices through the Local Authorised Representative (LAR), the in-country entity legally responsible for a registered device under the Medical Device Authority (MDA). Decide the registration holder before you decide distribution.

Key Takeaways

– The FRP Abbreviated Review is the dependable codified route for FDA or EMA approved drugs at a 90 working day target, against 245 for standard full evaluation. Default to it unless the pilot clearly fits.

– The Recognition Procedure Pilot (2 May 2026 for one year) targets 60 working days but is restricted to US FDA and EMA products submitted within three months of reference approval, and is not yet codified.

– The reference agency list, not the timeline, is the first eligibility gate. Seven agencies qualify for the Abbreviated Review; HSA Singapore is not among them.

– For Conditional Registration of new drugs and biologics, the product must already be registered in at least one DCA reference agency at submission, so sequence your global filings accordingly.

– Without a PRH or LAR structure you control, the expedited timelines deliver speed without commercial control. Decide the registration holder first.

> This briefing is for general information only. It does not constitute legal, regulatory, or medical advice. Regulatory requirements change. Verify all details against current official guidance before making filing or commercial decisions.

Foreign manufacturers assessing NPRA registration options can discuss pathway eligibility, PRH and LAR structuring, and dossier preparation with Infinity Pharmacare’s regulatory team.